Drug Delivery

St-Hubert Restaurants to Stock Allerject Epinephrine Auto-Injectors

The St-Hubert restaurant chain is teaming up with Sanofi Canada to stock Allerject epinephrine auto-injectors in all of its 117 locations in Quebec, Ontario, and New Brunswick, the company announced.

Lilly's Humalog 200 Units/mL KwikPen Now Available in U.S. Pharmacies

Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200), a concentrated mealtime insulin analog, is now available in pharmacies, Eli Lilly and Company announced. 

Humalog U-200 KwikPen is a prefilled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes. It is intended for people who are already taking mealtime insulin.

Pendopharm Announces Nasacort Allergy 24 Nasal Spray Available Without a Prescription in Ontario

Pendopharm, a division of Pharmascience Inc., announced that Nasacort Allergy 24HR nasal spray is now available over-the-counter (OTC) in Ontario for the temporary relief of numerous symptoms of perennial and seasonal allergic rhinitis, such as nasal congestion, runny nose, sneezing, and itchy nose. It applies to adults and children 12 years of age and older.

Adapt Pharma’s Narcan Nasal Spray Submitted to FDA to Treat Opioid Overdose

Lightlake Therapeutics Inc. announced that its partner for treating opioid overdose with intranasal naloxone, Adapt Pharma Limited, has submitted a new drug application to the FDA for Narcan Nasal Spray. It is an investigational drug intended to treat opioid overdose. 

Narcan Nasal Spray has been granted fast track designation by the FDA. The spray was developed in collaboration with the National Institutes on Drug Abuse (NIDA). 

Unilife Introduces World's First Instant Patch Pump for Insulin

Unilife Corporation announced the debut of its new Imperium platform of instant patch pumps for insulin.

FDA Approves the First 3D Printed Drug Product

Aprecia Pharmaceuticals Company announced the FDA has approved SPRITAM levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and children with epilepsy.

It is expected to be available in the first quarter of 2016. 

Breckenridge Announces Approval for Azelastine HCl Nasal Solution

Breckenridge Pharmaceutical, Inc. announced the immediate launch of Azelastine hydrochloride (HCl) Nasal Solution, 0.1 percent. 

According to the company, the FDA granted final approval for this Abbreviated New Drug Application (ANDA), which is AB rated to Astelin, a drug marketed by Meda Pharmaceuticals.

ANI Pharmaceuticals and Sofgen Announce FDA Approval of Nimodipine 30mg Capsules

ANI Pharmaceuticals, Inc. announced that its ANDA collaboration partner Sofgen has received approval from the FDA of the Abbreviated New Drug Application (ANDA) for Nimodipine 30mg Capsules.

“This represents ANI's first ANDA approval with our partner Sofgen,” says Arthur S. Przybyl, president and CEO of ANI, in a released statement. “We are excited to have achieved this milestone and look forward to a successful launch.”

Novo Nordisk’s FlexPro PenMate Hides Needle During Injection

Novo Nordisk announced the FDA’s approval of FlexPro PenMate, designed for users of Norditropin FlexPro 5 mg, 10 mg, and 15 mg pens who dislike needles and prefer them to be hidden during the injection process. 

Leti and Diabeloop Artificial Pancreas Project Targets Diabetes Treatment

CEA-Leti and Diabeloop announced their joint lab to develop an artificial pancreas to improve treatment for Type 1 diabetes patients. The lab builds on an earlier joint three-year research project that included clinical trials in hospitals and demonstrated the promise of a closed-loop system for treating diabetes.

Syndicate content